Predictive Value of the Pattern of β-Catenin Expression for Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients |
Elsamany, S
(Oncology, King Abdullah Medical City)
Elemam, O (Oncology, King Abdullah Medical City) Elmorsy, S (Pharmacology, Faculty of Medicine, Cairo University) Alzahrani, A (Oncology, King Abdullah Medical City) Abbas, MM (Pathology, King Abdullah Medical City) |
1 | Sinnberg T, Menzel M, Ewerth D, et al (2011). -Catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance. PLoS ONE, 6, 23429. DOI |
2 | van der Hage J, van de Velde C, Julien J, et al (2001). Preoperative chemotherapy in primary operable breast cancer: results from the european organization for research and treatment of cancer trial 10902. J Clin Oncol, 19, 4224-37. DOI |
3 | Wong SC, Lo SF, Lee KC, et al (2002). Expression of frizzled related protein and Wnt-signalling molecules in invasive human breast tumours. J Pathol, 196, 145-53. DOI |
4 | Xu WH, Liu ZB, Yang C, et al (2012). Expression of dickkopf-1 and beta-catenin related to the prognosis of breast cancer patients with triple negative phenotype. PLoS ONE, 7, 37624. DOI |
5 | Bear H, Anderson S, Smith R, et al (2006). Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol, 24, 2019-27. DOI |
6 | Bertolo C, Guerrero D, Vicente F, et al (2008). Differences and molecular immunohistochemical parameters in the subtypes of infiltrating ductal breast cancer. Am J Clin Pathol, 130, 414-24. DOI |
7 | Chung GG, Zerkowski MP, Ocal IT, et al (2004). beta-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer, 100, 2084-92. DOI |
8 | Bukholm IK, Nesland JM, Karesen R, et al (1998). E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol, 185, 262-6. DOI |
9 | Chan DSM, Vieira AR, Aune D, et al (2014). Body mass index and survival in women with breast cancer- systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol, 25, 1901 - 1914. DOI |
10 | Chau WK, Ip CK, Mak AS, et al (2012). c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/b-catenin-ATPbinding cassette G2 signaling. Oncogene, 10, 103. |
11 | Fisher B, Bryant J, Wolmark N, et al (1998). Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol, 16, 2672-85. DOI |
12 | Clevers H (2006). Wnt/beta-catenin signaling in development and disease. Cell, 127, 469-80. DOI |
13 | Cortazar P, Zhang L, Untch M, et al (2014). Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, 384 , 164-72. DOI |
14 | Dolled-Filhart M, McCabe A, Giltnane J, et al (2006). Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res, 66, 5487-94. DOI |
15 | Dawood S, Broglio K, Gonzalez-Angulo AM, et al (2008). Prognostic Value of Body Mass Index in Locally Advanced Breast Cancer. Clin Cancer Res, 14, 1718-25. DOI |
16 | Fanelli MA, Montt-Guevara M, Diblasi AM, et al (2008). P-Cadherin and -catenin are useful prognostic markers in breast cancer patients; -catenin interacts with heat shock protein Hsp27. Cell Stress Chaperones, 13, 207-20. DOI |
17 | Geyer FC, Lacroix-Triki M, Savage K, et al (2011). -Catenin pathway activation in breast cancer is associated with triplenegative phenotype but not with CTNNB1 mutation. Mod Pathol, 24, 209-31. DOI |
18 | Hess K, Anderson K, Symmans W, et al (2006). Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast can. J Clin Oncol, 24, 4236-44. DOI |
19 | Jiang Y, Zou L, Zhang C, et al (2009). PPARgamma and Wnt/- Catenin pathway in human breast cancer: expression pattern, molecular interaction and clinical/prognostic correlations. J Cancer Res Clin Oncol, 135, 1551-9. DOI |
20 | Khramtsov AI, Khramtsova GF, Tretiakova M, et al (2010). Wnt/beta-catenin pathway activation is enriched in basallike breast cancers and predicts poor outcome. Am J Pathol, 176, 2911-20. DOI |
21 | Li S, Sun Y, Li L (2014). The expression of -catenin in different subtypes of breast cancer and its clinical significance. Tumor Biol, 35, 7693-8. DOI |
22 | Lin SY, Xia W, Wang JC, et al (2000). Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA, 97, 4262-6. DOI |
23 | Lopez-Knowles E, Zardawi SJ, McNeil CM, et al (2010). Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev, 19, 301-9. DOI |
24 | Nelson WJ, Nusse R (2004). Convergence of Wnt, beta-catenin, and cadherin pathways. Science, 303, 1483-7. DOI |
25 | Nolen B, Marks J, Ta’san S, et al (2008). Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res, 10, 45. |
26 | Pedersen KB, Nesland JM, Fodstad O, et al (2002). Expression of S100A4, E-cadherin, alpha- and beta-catenin in breast cancer biopsies. Br J Cancer, 87, 1281-6. DOI |
27 | Prasad CP, Gupta SD, Rath G, et al (2007). Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between beta-catenin, dishevelled and cyclin D1 expression. Oncol, 73, 112-117. DOI |
28 | Rouzier R, Perou C, Symmans W, et al (2005). Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res,11, 5678-85. DOI |
29 | Prosperi JR, Goss KH (2010). AWnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer. Curr Drug Targets, 11, 1074-88. DOI |